诺诚健华(09969.HK) 公布，国家药监局已批准Minjuvi(tafasitamab)与来那度胺联合治疗不适合作自体干细胞移植(ASCT)的复发或难治性弥漫性大B细胞淋巴瘤(DLBCL)的成年患者。
公司指，此疗法已获准于香港、澳门及台湾地区治疗符合条件的DLBCL患者，并于瑞金海南医院及广东祈福医院为符合条件的DLBCL患者给药。另外，Tafasitamab已经获得美国食品药品监督管理局(FDA)加速批准，以及欧洲药品管理局(EMA)有条件批准与来那度胺联合治疗不符合ASCT条件的复发或难治DLBCL成人患者。(ss/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-21 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.